drugset / Trial / NCT03763604

Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

NCT03763604

Expanded access Approved for marketing Eli Lilly and Company

Summary

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Abemaciclib Small molecule Oral

Indications